Qualigen Therapeutics, Inc. (QLGN)
After hours:
- GlobeNewswire
Qualigen Therapeutics to Present at BIO International Convention
Qualigen Therapeutics, Inc. Tariq Arshad CARLSBAD, Calif., June 14, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today announces that Qualigen Therapeutics will present a corporate overview at the BIO International Convention to be held on June 13 – 16, 2022 at the San Diego Convention Cent
- GlobeNewswire
Qualigen Therapeutics Announces IND-Enabling Studies to Advance Lead Program QN-302 Toward Clinical Trials
A Potential Treatment for Pancreatic Cancer in Addition to Other Tumors of High Unmet Clinical Need CARLSBAD, Calif., June 07, 2022 (GLOBE NEWSWIRE) -- Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life sciences company focused on developing treatments for adult and pediatric cancers with potential for Orphan Drug Designation, while also commercializing diagnostics, today announces it has initiated Investigational New Drug, or IND-enabling, studies for its lead therapeutic program, Q
- Zacks Small Cap Research
QLGN: Acquires Majority Stake in Israeli Diagnostics Technology Company NanoSynex…
By David Bautz, PhD NASDAQ:QLGN READ THE FULL QLGN RESEARCH REPORT Business Update Acquires Majority Stake in NanoSynex On May 3, 2022, Qualigen Therapeutics, Inc. (NASDAQ:QLGN) entered into a definitive agreement to acquire a majority stake in NanoSynex Ltd., an Israeli-based diagnostics company developing the Antimicrobial Susceptibility Testing (AST) platform. The goal of AST is to provide
